Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Previous recommendations on who should be vaccinated with the H1N1 pandemic influenza vaccine still stand according to the World WHO's Strategic Advisory Group of Experts on Immunization, the principal advisory group to WHO for development of policy related to vaccines and immunization.
PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today issued its Interim Management Statement covering the period January 1, 2010, to March 31, 2010.
PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announced its Final Results for the year ending December 31, 2009, and the availability of its 2009 annual report on its website.
The first head to head study of the two H1N1 vaccines used in the UK during the recent pandemic finds that the adjuvanted split virus vaccine induced higher immune response rates in young children, but was associated with more reactions than the whole virus vaccine.
Fear of the H1N1 virus appears to be the driving factor behind the adoption of preventive behaviors, according to a study published in the June issue of AJIC: American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.
In a tropical environment, influenza A(H1N1) appeared milder than seasonal flu, was less likely to cause fever and upset stomach and more likely to infect younger individuals, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.
Future pandemics of seasonal flu, H1N1 and other drug-resistant viruses may be thwarted by a potent, immune-boosting payload that is effectively delivered to cells by gold nanorods, report scientists at the University at Buffalo and the U.S. Centers for Disease Control and Prevention. The work is published in the current issue of the Proceedings of the National Academy of Sciences.
Pregnant women who contract the H1N1 flu strain are at risk for obstetrical complications including fetal distress, premature delivery, emergency cesarean delivery and fetal death, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration has issued 510(k) clearance to the Simplexa Influenza A H1N1 (2009) test on the 3M Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is the first to be cleared by the FDA for use as an aid in the detection and differentiation of influenza A and 2009 H1N1 influenza viral RNA.
The U.S. Food and Drug Administration today announced it has cleared the Simplexa Influenza A H1N1 (2009), a test for the 2009 H1N1 Influenza Virus in patients with signs and symptoms of respiratory infection.
NanoViricides, Inc., has filed its quarterly report with the Securities and Exchange Commission on Thursday, May 20th, in a timely fashion.
From the 63rd World Health Assembly (WHA) in Geneva, the Associated Press reports on what some "describe as a new strategy to get rid of" polio that focuses on developing solutions to "problems in each country, provides more WHO monitoring, like more teleconferences, and holds governments more accountable." The plans also provide "[n]ew [polio] outbreak response plans," according to the AP.
Despite concerns from public health officials, influenza antiviral drugs were not hoarded during the recent H1N1 flu season, according to a new analysis presented recently at the Academy of Managed Care Pharmacy's 22nd Annual Meeting in San Diego by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management.
BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.
In growing numbers, children across America are adding a dose of medicine to their daily routine. In 2009, drug trend for children – a measure of prescription spending growth – increased 10.8 percent, driven by a 5 percent increase in drug utilization and higher medication costs, according to the Medco 2010 Drug Trend Report. The growth in prescription drug use among children was nearly four times higher than the rise seen in the overall population.
The latest research to combat emerging infectious diseases threatening Australia is being presented at the Sydney Institute of Emerging Infectious Diseases and Biosecurity Conference at the University of Sydney today.
Yearly vaccinations aren't just for kids any more. You probably heard a lot about a seasonal or H1N1 flu shot last fall, but you should know that a battery of other adult vaccinations might also become part of your health care routine. Pneumonia and shingles vaccines are preventive-care essentials for older adults, and meningitis and tetanus shots are now college rites of passage. Even the vaccines of childhood—measles, mumps and rubella, and whooping cough—are recommended for adults who missed out in their younger years.
During her opening address to the World Health Assembly in Geneva, Switzerland, on Monday, WHO Director-General Margaret Chan called for increased global efforts to reach the Millennium Development Goals, PANA/Afrique en ligne reports. Chan also set-up several global health challenges to be addressed during the five-day meeting, according to the news service.
BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.